Please wait while the formulary information is being retrieved.
Drug overview for ROTATEQ (rotavirus vaccine, live oral pentavalent):
Generic name: ROTAVIRUS VACCINE, LIVE ORAL PENTAVALENT (roe-TUH VYE-russ)
Drug class: Rotavirus Vaccines
Therapeutic class: Biologicals
Rotavirus vaccine is commercially available in the US as a monovalent live, attenuated virus vaccine derived from a human rotavirus strain (Rotarix(R); RV1) and as a pentavalent live virus vaccine containing 5 live, reassortant rotaviruses derived from human and bovine hosts (RotaTeq(R); RV5). Some other rotavirus vaccines (e.g., other monovalent or multivalent human-animal reassortant vaccines) are being investigated or may be available in other countries.
No enhanced Uses information available for this drug.
Generic name: ROTAVIRUS VACCINE, LIVE ORAL PENTAVALENT (roe-TUH VYE-russ)
Drug class: Rotavirus Vaccines
Therapeutic class: Biologicals
Rotavirus vaccine is commercially available in the US as a monovalent live, attenuated virus vaccine derived from a human rotavirus strain (Rotarix(R); RV1) and as a pentavalent live virus vaccine containing 5 live, reassortant rotaviruses derived from human and bovine hosts (RotaTeq(R); RV5). Some other rotavirus vaccines (e.g., other monovalent or multivalent human-animal reassortant vaccines) are being investigated or may be available in other countries.
No enhanced Uses information available for this drug.
DRUG IMAGES
ROTATEQ VACCINE
The following indications for ROTATEQ (rotavirus vaccine, live oral pentavalent) have been approved by the FDA:
Indications:
Rotavirus vaccination
Professional Synonyms:
Active immunization against rotavirus
Active immunization for the prevention of rotavirus gastroenteritis
Gastroenteritis due to rotavirus prophylaxis
Rotavirus gastroenteritis prevention
Rotavirus gastroenteritis prophylaxis
Vaccination to prevent rotavirus gastroenteritis
Indications:
Rotavirus vaccination
Professional Synonyms:
Active immunization against rotavirus
Active immunization for the prevention of rotavirus gastroenteritis
Gastroenteritis due to rotavirus prophylaxis
Rotavirus gastroenteritis prevention
Rotavirus gastroenteritis prophylaxis
Vaccination to prevent rotavirus gastroenteritis
The following dosing information is available for ROTATEQ (rotavirus vaccine, live oral pentavalent):
Dosage and dosing schedule (i.e., number and timing of doses) differ depending on the specific vaccine (Rotarix(R) or RotaTeq(R)) administered. Dosage recommendations for the specific vaccine used should be followed.
Data not available regarding interchangeability of rotavirus vaccines. The specific rotavirus vaccine (Rotarix(R) or RotaTeq(R)) used for the initial dose should be used to complete the vaccination series, whenever possible. If the specific rotavirus vaccine used for previous doses is unknown or unavailable, the vaccination series should be continued or completed with the currently available rotavirus vaccine; vaccination should not be deferred.
If RotaTeq(R) or an unknown rotavirus vaccine was administered for any dose in the vaccination series, a total of 3 primary doses should be administered to complete the series.
ACIP and AAP state that the first dose of rotavirus vaccine should be given at 6 weeks through 14 weeks of age (up to 14 weeks 6 days of age). Because of insufficient data, ACIP and AAP state that the vaccination series should not be initiated in infants who are 15 weeks of age or older. If the first dose of rotavirus vaccine is inadvertently administered to an infant 15 weeks of age or older, the remainder of the series should be completed according to the usually recommended vaccination schedule since timing of the first vaccine dose should not affect the safety and efficacy of subsequent doses.
Preterm infants who are medically stable should receive rotavirus vaccine at the usual chronologic age using the usual dosage, provided the vaccine is administered to the age-eligible infant after or at the time of discharge from the neonatal intensive care unit (NICU) or hospital nursery. Possible risk of transmission of rotavirus vaccine virus to other hospitalized infants outweigh benefits of vaccination in age-eligible infants who will remain in the NICU or hospital nursery after the dose. (See Pediatric Use under Warnings/Precautions: Specific Populations, in Cautions.)
Because natural rotavirus infection frequently provides only partial immunity, ACIP and AAP recommend that the rotavirus vaccination series be initiated or completed in infants who had rotavirus gastroenteritis before receiving the complete series.
Data not available regarding interchangeability of rotavirus vaccines. The specific rotavirus vaccine (Rotarix(R) or RotaTeq(R)) used for the initial dose should be used to complete the vaccination series, whenever possible. If the specific rotavirus vaccine used for previous doses is unknown or unavailable, the vaccination series should be continued or completed with the currently available rotavirus vaccine; vaccination should not be deferred.
If RotaTeq(R) or an unknown rotavirus vaccine was administered for any dose in the vaccination series, a total of 3 primary doses should be administered to complete the series.
ACIP and AAP state that the first dose of rotavirus vaccine should be given at 6 weeks through 14 weeks of age (up to 14 weeks 6 days of age). Because of insufficient data, ACIP and AAP state that the vaccination series should not be initiated in infants who are 15 weeks of age or older. If the first dose of rotavirus vaccine is inadvertently administered to an infant 15 weeks of age or older, the remainder of the series should be completed according to the usually recommended vaccination schedule since timing of the first vaccine dose should not affect the safety and efficacy of subsequent doses.
Preterm infants who are medically stable should receive rotavirus vaccine at the usual chronologic age using the usual dosage, provided the vaccine is administered to the age-eligible infant after or at the time of discharge from the neonatal intensive care unit (NICU) or hospital nursery. Possible risk of transmission of rotavirus vaccine virus to other hospitalized infants outweigh benefits of vaccination in age-eligible infants who will remain in the NICU or hospital nursery after the dose. (See Pediatric Use under Warnings/Precautions: Specific Populations, in Cautions.)
Because natural rotavirus infection frequently provides only partial immunity, ACIP and AAP recommend that the rotavirus vaccination series be initiated or completed in infants who had rotavirus gastroenteritis before receiving the complete series.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ROTATEQ (rotavirus vaccine, live oral pentavalent):
There are 3 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Vaccines; Live BCG/Selected Immunosuppressive Agents SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: A variety of disease modifying agents suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(2) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) Patients who receive anti-B cell therapies should not receive live vaccines for at least 6 months after such therapies due to a prolonged duration of immunosuppression. An exception is the Zoster vaccine, which can be given at least 1 month after receipt of anti-B cell therapies.(1) The US manufacturer of abatacept states live vaccines should not be given during or for up to 3 months after discontinuation of abatacept.(2) The US manufacturer of live BCG for intravesicular treatment of bladder cancer states use is contraindicated in immunosuppressed patients.(3) The US manufacturer of daclizumab states live vaccines are not recommended during and for up to 4 months after discontinuation of treatment.(4) The US manufacturer of guselkumab states that live vaccines should be avoided during treatment with guselkumab.(5) The US manufacturer of inebilizumab-cdon states that live vaccines are not recommended during treatment and after discontinuation until B-cell repletion. Administer all live vaccinations at least 4 weeks prior to initiation of inebilizumab-cdon.(6) The US manufacturer of ocrelizumab states that live vaccines are not recommended during treatment and until B-cell repletion occurs after discontinuation of therapy. Administer all live vaccines at least 4 weeks prior to initiation of ocrelizumab.(7) The US manufacturer of ozanimod states that live vaccines should be avoided during and for up to 3 months after discontinuation of ozanimod.(8) The US manufacturer of siponimod states that live vaccines are not recommended during treatment and for up to 4 weeks after discontinuation of treatment.(9) The US manufacturer of ustekinumab states BCG vaccines should not be given in the year prior to, during, or the year after ustekinumab therapy.(10) The US manufacturer of satralizumab-mwge states that live vaccines are not recommended during treatment and should be administered at least four weeks prior to initiation of satralizumab-mwge.(11) The US manufacturer of ublituximab-xiiy states that live vaccines are not recommended during treatment and until B-cell recovery. Live vaccines should be administered at least 4 weeks prior to initiation of ublituximab-xiiy.(12) The US manufacturer of etrasimod states that live vaccines should be avoided during and for 5 weeks after treatment. Live vaccines should be administered at least 4 weeks prior to initiation of etrasimod.(13) The US manufacturer of emapalumab-lzsg states that live vaccines should not be administered to patients receiving emapalumab-lzsg and for at least 4 weeks after the last dose of emapalumab-lzsg. The safety of immunization with live vaccines during or following emapalumab-lzsg therapy has not been studied.(14) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1) |
ABECMA, ABRAXANE, ABRILADA(CF), ABRILADA(CF) PEN, ABRILADA(CF) PEN (2 PACK), ACTEMRA, ACTEMRA ACTPEN, ACTIMMUNE, ADALIMUMAB-AACF(CF), ADALIMUMAB-AACF(CF) (2 PK), ADALIMUMAB-AACF(CF) PEN (2 PK), ADALIMUMAB-AACF(CF) PEN CROHNS, ADALIMUMAB-AACF(CF) PEN PS-UV, ADALIMUMAB-AATY(CF) (2 PACK), ADALIMUMAB-AATY(CF) (2 PK), ADALIMUMAB-AATY(CF) AI CROHNS, ADALIMUMAB-AATY(CF) AUTOINJ(2), ADALIMUMAB-AATY(CF) AUTOINJECT, ADALIMUMAB-ADAZ(CF), ADALIMUMAB-ADAZ(CF) PEN, ADALIMUMAB-ADBM(CF), ADALIMUMAB-ADBM(CF) PEN, ADALIMUMAB-ADBM(CF) PEN CROHNS, ADALIMUMAB-ADBM(CF) PEN PS-UV, ADALIMUMAB-ADBM(CF)PEN, ADALIMUMAB-FKJP(CF), ADALIMUMAB-FKJP(CF) PEN, ADALIMUMAB-RYVK(CF), ADALIMUMAB-RYVK(CF) AUTOINJECT, ADBRY, ADBRY AUTOINJECTOR, ADCETRIS, ADRIAMYCIN, ADRUCIL, AFINITOR, AFINITOR DISPERZ, AKEEGA, ALFERON N, ALIMTA, ALIQOPA, ALKERAN, ALUNBRIG, AMJEVITA(CF), AMJEVITA(CF) AUTOINJECTOR, AMTAGVI, ARAVA, ARCALYST, ARRANON, ARSENIC TRIOXIDE, ARZERRA, ASPARLAS, ASTAGRAF XL, ATGAM, AUBAGIO, AUCATZYL, AUGTYRO, AVONEX, AVONEX (4 PACK), AVONEX PEN, AVONEX PEN (4 PACK), AVSOLA, AXTLE, AZACITIDINE, AZASAN, AZATHIOPRINE, AZATHIOPRINE SODIUM, BAFIERTAM, BAVENCIO, BELEODAQ, BELRAPZO, BENDAMUSTINE HCL, BENDEKA, BENLYSTA, BESPONSA, BESREMI, BETASERON, BEXAROTENE, BICNU, BIMZELX, BIMZELX AUTOINJECTOR, BLEOMYCIN SULFATE, BLINCYTO, BORTEZOMIB, BORUZU, BOSULIF, BRAFTOVI, BREYANZI, BREYANZI CD4 COMPONENT, BREYANZI CD8 COMPONENT, BRIUMVI, BRUKINSA, BUSULFAN, BUSULFEX, CABOMETYX, CAELYX, CALQUENCE, CAMPATH, CAMPTOSAR, CAPECITABINE, CAPRELSA, CARBOPLATIN, CARMUSTINE, CARVYKTI, CELLCEPT, CHLORAMBUCIL, CIBINQO, CIMZIA, CIMZIA (2 PACK), CISPLATIN, CLADRIBINE, CLOFARABINE, COLUMVI, COMETRIQ, COPIKTRA, COSENTYX, COSENTYX (2 SYRINGES), COSENTYX SENSOREADY (2 PENS), COSENTYX SENSOREADY PEN, COSENTYX SYRINGE, COSENTYX UNOREADY PEN, COSMEGEN, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, CYCLOSPORINE, CYCLOSPORINE MODIFIED, CYLTEZO(CF), CYLTEZO(CF) PEN, CYLTEZO(CF) PEN CROHN'S-UC-HS, CYLTEZO(CF) PEN PSORIASIS-UV, CYTARABINE, DACARBAZINE, DACTINOMYCIN, DANZITEN, DARAPRIM, DARZALEX, DARZALEX FASPRO, DASATINIB, DAUNORUBICIN HCL, DAURISMO, DECITABINE, DEXRAZOXANE, DIMETHYL FUMARATE, DOCETAXEL, DOCIVYX, DOXIL, DOXORUBICIN HCL, DOXORUBICIN HCL LIPOSOME, DUPIXENT PEN, DUPIXENT SYRINGE, EBGLYSS PEN, EBGLYSS SYRINGE, EFLORNITHINE HCL, ELAHERE, ELLENCE, ELREXFIO, ENBREL, ENBREL MINI, ENBREL SURECLICK, ENHERTU, ENSPRYNG, ENTYVIO, ENTYVIO PEN, ENVARSUS XR, EPIRUBICIN HCL, EPKINLY, ERBITUX, ERLOTINIB HCL, ERWINASE, ETOPOPHOS, ETOPOSIDE, EVEROLIMUS, EVOMELA, FARESTON, FARYDAK, FINGOLIMOD, FLOXURIDINE, FLUDARABINE PHOSPHATE, FLUOROURACIL, FOLOTYN, FRINDOVYX, FYARRO, GAMIFANT, GAVRETO, GAZYVA, GEFITINIB, GEMCITABINE HCL, GENGRAF, GILENYA, GLEEVEC, GLEOSTINE, GLIADEL, GRAFAPEX, HADLIMA, HADLIMA PUSHTOUCH, HADLIMA(CF), HADLIMA(CF) PUSHTOUCH, HEPZATO, HERCEPTIN, HERCEPTIN HYLECTA, HERCESSI, HERZUMA, HICON, HULIO(CF), HULIO(CF) PEN, HUMIRA, HUMIRA PEN, HUMIRA(CF), HUMIRA(CF) PEN, HUMIRA(CF) PEN CROHN'S-UC-HS, HUMIRA(CF) PEN PSOR-UV-ADOL HS, HYCAMTIN, HYRIMOZ, HYRIMOZ PEN, HYRIMOZ(CF), HYRIMOZ(CF) PEDIATRIC CROHN'S, HYRIMOZ(CF) PEN, HYRIMOZ(CF) PEN CROHN-UC START, HYRIMOZ(CF) PEN PSORIASIS, ICLUSIG, IDAMYCIN PFS, IDARUBICIN HCL, IFEX, IFOSFAMIDE, ILARIS, ILUMYA, IMATINIB MESYLATE, IMBRUVICA, IMDELLTRA, IMFINZI, IMKELDI, IMURAN, INFLECTRA, INFLIXIMAB, INFUGEM, INQOVI, INREBIC, IRESSA, IRINOTECAN HCL, ISTODAX, IVRA, IWILFIN, IXEMPRA, JAKAFI, JAYPIRCA, JEMPERLI, JEVTANA, KADCYLA, KANJINTI, KEMOPLAT, KESIMPTA PEN, KEVZARA, KEYTRUDA, KINERET, KISQALI, KYMRIAH, LEFLUNICLO, LEFLUNOMIDE, LEMTRADA, LENALIDOMIDE, LEUKERAN, LEVAMISOLE HCL, LITFULO, LONSURF, LOQTORZI, LUNSUMIO, LUPKYNIS, LUTATHERA, LYNPARZA, MATULANE, MAVENCLAD, MAYZENT, MECHLORETHAMINE HCL, MEKINIST, MEKTOVI, MELPHALAN HCL, MERCAPTOPURINE, METHOTREXATE, METHOTREXATE SODIUM, MITOMYCIN, MITOXANTRONE HCL, MONJUVI, MUTAMYCIN, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, MYFORTIC, MYHIBBIN, MYLERAN, MYLOTARG, NELARABINE, NEMLUVIO, NEORAL, NEXAVAR, NILOTINIB HCL, NIPENT, NULOJIX, OCREVUS, OCREVUS ZUNOVO, OGIVRI, OJJAARA, OLUMIANT, OMVOH, OMVOH PEN, ONCASPAR, ONIVYDE, ONTRUZANT, ONUREG, OPDIVO, OPDIVO QVANTIG, OPDUALAG, ORENCIA, ORENCIA CLICKJECT, OTULFI, OXALIPLATIN, PACLITAXEL, PACLITAXEL PROTEIN-BOUND, PARAPLATIN, PAZOPANIB HCL, PEGASYS, PEMETREXED, PEMETREXED DISODIUM, PEMFEXY, PEMRYDI RTU, PERJETA, PHESGO, PLEGRIDY, PLEGRIDY PEN, PLUVICTO, POLIVY, POMALYST, PONVORY, POTELIGEO, PRALATREXATE, PROCARBAZINE HCL, PROGRAF, PROLEUKIN, PURIXAN, PYRIMETHAMINE, PYZCHIVA, QUALAQUIN, QUININE HCL, QUININE SULFATE, REBIF, REBIF REBIDOSE, REMICADE, RENFLEXIS, REVLIMID, REVUFORJ, REZUROCK, RIABNI, RINVOQ, RINVOQ LQ, RITUXAN, RITUXAN HYCELA, ROMIDEPSIN, RUBRACA, RUXIENCE, RYDAPT, RYLAZE, RYSTIGGO, RYTELO, SANDIMMUNE, SAPHNELO, SARCLISA, SCEMBLIX, SELARSDI, SILIQ, SIMLANDI(CF), SIMLANDI(CF) AUTOINJECTOR, SIMPONI, SIMPONI ARIA, SIMULECT, SIROLIMUS, SKYRIZI, SKYRIZI ON-BODY, SKYRIZI PEN, SODIUM IODIDE I-131, SORAFENIB, SOTYKTU, SPEVIGO, SPRYCEL, STELARA, STEQEYMA, STIVARGA, STRONTIUM-89 CHLORIDE, SUNITINIB MALATE, SUTENT, SYLVANT, TABLOID, TACROLIMUS, TACROLIMUS XL, TALTZ AUTOINJECTOR, TALTZ AUTOINJECTOR (2 PACK), TALTZ AUTOINJECTOR (3 PACK), TALTZ SYRINGE, TALVEY, TALZENNA, TARCEVA, TARGRETIN, TASCENSO ODT, TASIGNA, TECARTUS, TECELRA, TECENTRIQ, TECENTRIQ HYBREZA, TECFIDERA, TECVAYLI, TEMODAR, TEMOZOLOMIDE, TEMSIROLIMUS, TEPADINA, TERIFLUNOMIDE, TEVIMBRA, TEZSPIRE, THALOMID, THIOGUANINE, THIOTEPA, THYMOGLOBULIN, TOFACITINIB CITRATE, TOFIDENCE, TOPOTECAN HCL, TOREMIFENE CITRATE, TORISEL, TORPENZ, TRAMETINIB, TRAZIMERA, TREANDA, TREMFYA, TREMFYA PEN, TREMFYA PEN INDUCTION PK-CROHN, TRIFLURIDINE, TRISENOX, TRUQAP, TRUXIMA, TYENNE, TYENNE AUTOINJECTOR, TYSABRI, UNITUXIN, UPLIZNA, USTEKINUMAB, USTEKINUMAB-TTWE, VALRUBICIN, VALSTAR, VANFLYTA, VELCADE, VELSIPITY, VENCLEXTA, VENCLEXTA STARTING PACK, VERZENIO, VIDAZA, VINBLASTINE SULFATE, VINCASAR PFS, VINCRISTINE SULFATE, VINORELBINE TARTRATE, VITRAKVI, VIVIMUSTA, VOTRIENT, VYVGART, VYVGART HYTRULO, VYXEOS, WEZLANA, XALKORI, XELJANZ, XELJANZ XR, XELODA, XOFIGO, XPOVIO, YESCARTA, YESINTEK, YONDELIS, YUFLYMA(CF) (2 PACK), YUFLYMA(CF) AI CROHN'S-UC-HS, YUFLYMA(CF) AUTOINJECT (2 PCK), YUFLYMA(CF) AUTOINJECTOR, YUSIMRY(CF) PEN, ZEJULA, ZEPOSIA, ZEPZELCA, ZEVALIN, ZOKINVY, ZORTRESS, ZYDELIG, ZYMFENTRA, ZYMFENTRA (2 PACK), ZYMFENTRA PEN (2 PACK), ZYNYZ |
| Selected Live Viral Vaccines/Rho Immunoglobulin SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Immune globulin products may prevent the immune system from properly responding to the vaccine.(1-6) CLINICAL EFFECTS: Administration of a live viral vaccine after immunoglobulins may impair the efficacy of the vaccine.(1-6) Administration of immunoglobulins within 2-4 weeks after a live viral vaccine impair the efficacy of the vaccine.(1-6) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Administration of a live viral vaccine should be postponed for three months in patients who have received immunoglobulin therapy, including Rho immunoglobulin.(1-6) If a live viral vaccine is given within two to four weeks of rho immunoglobulin, then repeat vaccination three months after the completion of immunoglobulin should be considered.(2-4) DISCUSSION: Administration of a live viral vaccine after immunoglobulins(1-6) or administration of immunoglobulins after a live vaccine(3) may impair the efficacy of the vaccine. |
HYPERRHO S-D, RHOGAM ULTRA-FILTERED PLUS, RHOPHYLAC, WINRHO SDF |
| Live Vaccines/Bevacizumab SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Systemic bevacizumab suppresses the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines. Immune response to vaccines may be decreased during periods of immunocompromise.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. Intravitreal injections of small doses of bevacizumab for macular degeneration or macular edema are not expected to suppress immune function. PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) Intravitreal injections of small doses of bevacizumab for macular degeneration or macular edema are not expected to suppress immune function. For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1) |
ALYMSYS, AVASTIN, MVASI, VEGZELMA, ZIRABEV |
There are 6 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Systemic Corticosteroids; Corticotropin (ACTH)/Live Vaccines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Corticosteroids and corticotropin suppress the immune system. In severely immunocompromised patients, virus replication after administration of live, attenuated-virus vaccines can be enhanced and/or the immune response to the vaccine may be decreased.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) PREDISPOSING FACTORS: Patients receiving immunosuppressive doses of corticosteroids or corticotropin for equal to or greater than 14 consecutive days.(1) PATIENT MANAGEMENT: The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are severely immunosuppressed, including those who are receiving or have received high-dose, systemic steroids for greater than or equal to 14 consecutive days. Live vaccines should be deferred for at least 1 month after discontinuation of high-dose systemic steroids administered for 14 consecutive days. When initiating immunosuppressives doses of corticosteroids, wait 4 weeks after a live vaccines is administered. However, if patients require therapy for chronic inflammatory conditions, do not delay therapy due to past vaccines. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued.(1) The US manufacturer of corticotropin(2) and triamcinolone(3) and the Australian manufacturer of dexamethasone(4) state that administration of live or live-attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids or corticotropin. The manufacturer of deflazacort states that live or live-attenuated vaccines should be administered at least 4 to 6 weeks prior to initiation of therapy with deflazacort.(5) DISCUSSION: Many clinicians consider a dose equivalent to either 2 mg/kg of body weight or a total of 20 mg/day of prednisone as sufficiently immunosuppressive to raise safety concerns about live-virus vaccines.(1) Immunization procedures may be undertaken in patients receiving corticosteroids when the therapy is short term (less than 2 weeks); low to moderate dose; long-term, alternate-day treatment with short-acting preparations; maintenance physiologic doses (replacement therapy); or administered topically (skin or eyes), by aerosol, or by intra-articular, bursal, or tendon injection.(1) Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) |
ACTHAR, ACTHAR SELFJECT, ADRENOCORTICOTROPHIC HORMONE, AGAMREE, ALDOSTERONE, ALKINDI SPRINKLE, ANUCORT-HC, ANUSOL-HC, BECLOMETHASONE DIPROPIONATE, BETA 1, BETALOAN SUIK, BETAMETHASONE ACETATE MICRO, BETAMETHASONE ACETATE-SOD PHOS, BETAMETHASONE DIPROPIONATE, BETAMETHASONE SOD PHOS-ACETATE, BETAMETHASONE SOD PHOS-WATER, BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE VALERATE, BSP 0820, BUDESONIDE, BUDESONIDE DR, BUDESONIDE EC, BUDESONIDE ER, BUDESONIDE MICRONIZED, BUPIVACAINE-DEXAMETH-EPINEPHRN, CELESTONE, CLOBETASOL PROPIONATE MICRO, CORTEF, CORTENEMA, CORTICOTROPHIN, CORTIFOAM, CORTISONE ACETATE, CORTROPHIN, DEFLAZACORT, DEPO-MEDROL, DESONIDE MICRONIZED, DESOXIMETASONE, DESOXYCORTICOSTERONE ACETATE, DEXABLISS, DEXAMETHASONE, DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE MICRO, DEXAMETHASONE INTENSOL, DEXAMETHASONE ISONICOTINATE, DEXAMETHASONE MICRONIZED, DEXAMETHASONE SOD PHOS-WATER, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE-0.9% NACL, DMT SUIK, DOUBLEDEX, EMFLAZA, EOHILIA, FLUDROCORTISONE ACETATE, FLUNISOLIDE, FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE MICRO, FLUOCINONIDE MICRONIZED, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE MICRO, HEMADY, HEMMOREX-HC, HEXATRIONE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE SOD SUCCINATE, KENALOG-10, KENALOG-40, KENALOG-80, LIDOCIDEX-I, MAS CARE-PAK, MEDROL, MEDROLOAN II SUIK, MEDROLOAN SUIK, METHYLPREDNISOLONE, METHYLPREDNISOLONE AC MICRO, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, MILLIPRED, MILLIPRED DP, MOMETASONE FUROATE, ORAPRED ODT, ORTIKOS, PEDIAPRED, PREDNISOLONE, PREDNISOLONE ACETATE MICRONIZE, PREDNISOLONE MICRONIZED, PREDNISOLONE SODIUM PHOS ODT, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE, PREDNISONE INTENSOL, PREDNISONE MICRONIZED, PRO-C-DURE 5, PRO-C-DURE 6, PROCTOCORT, RAYOS, SOLU-CORTEF, SOLU-MEDROL, TAPERDEX, TARPEYO, TRIAMCINOLONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE MICRO, TRILOAN II SUIK, TRILOAN SUIK, UCERIS, VERIPRED 20, ZCORT |
| Live Vaccines/Methotrexate (low strength injection, oral) SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: A variety of disease modifying agents such as methotrexate suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines. Immune response to vaccines may be decreased during periods of immunocompromise.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) CDC recommendations for zoster vaccine state it may be administered to patients receiving methotrexate if the dose is < or = to 0.4 mg/kg/week for treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease or other conditions.(1) For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1) |
METHOTREXATE, OTREXUP, RASUVO, TREXALL, XATMEP |
| Tuberculin Testing/Live Vaccines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Measles infection and severe acute and chronic infections may induce an anergic state resulting in a false-negative tuberculin test. The live measles vaccine, as well as other live vaccines (e.g. smallpox, varicella, yellow fever) theoretically may also suppress response to tuberculin testing, though the degree of suppression may be less than that expected from acute infection with wild-type virus.(1-4) CLINICAL EFFECTS: Tuberculin testing that is performed more than one day but less than 28 days after administration of a live vaccine may result in a false negative tuberculin response. Tuberculin testing may be administered simultaneously with live vaccines.(1-4) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The CDC states that live vaccines (e.g. MMR and varicella) and tuberculin testing may be administered within one day of each other at separate administration sites. If it has been more than one day since tuberculin testing has been administered, the live vaccine can be given at any interval after the tuberculin test. However, if the live vaccine has been administered more than one day previously and tuberculin testing is indicated, tuberculin testing should be deferred for at least 4-6 weeks.(1-4) DISCUSSION: Suppression of response to tuberculin testing has been observed following measles infection, live measles vaccination, and live smallpox vaccination. The degree of suppression after live virus vaccination is likely to be less than that from an acute infection with wild-type virus. There is no data on suppression of response to tuberculin testing with other live vaccines. In the absence of data, the CDC recommends tuberculin testing within one day that a live vaccine is administered. Otherwise the tuberculin test should be deferred for at least 4-6 weeks.(1-4) |
APLISOL, TUBERSOL |
| Live Vaccines; Live BCG/Hydroxyurea SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Hydroxyurea may suppress the immune system.(1) Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(2) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(2) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(3) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies), treatments (e.g. radiation) and cytotoxic drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: Recommendations for administration of live vaccines in patients on hydroxyurea are dependent on the indication. The US manufacturers of hydroxyurea recommend avoiding live vaccine use in patients taking hydroxyurea. Evaluate hematologic status prior to and during treatment with hydroxyurea. Provide supportive care and modify the dose or discontinue hydroxyurea as needed.(1) The Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued.(2) The ACIP recommendations state that routine vaccinations patients with secondary immunodeficiency such as sickle cell disease are likely effective. Live viral and bacterial vaccines are contraindicated in patients with generalized malignant neoplasm, immunosuppressive, or radiation therapy, depending on immune status.(4) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(2) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(2) A multicenter, randomized, double-blind, placebo-controlled trial in infants and young children with sickle cell disease (BABY HUG) studied the response to pneumococcal and measles, mumps, and rubella vaccines in patients using hydroxyurea. The authors concluded that hydroxyurea does not appear to have significant deleterious effects on the immune function of infants and children with sickle cell disease. Additional assessments of lymphocyte parameters of hydroxyurea-treated children may be warranted. No changes in current immunization schedules are recommended; however, for endemic disease or epidemics, adherence to accelerated immunization schedules for the measles, mumps, and rubella vaccine should be reinforced.(5) |
DROXIA, HYDREA, HYDROXYUREA, SIKLOS, XROMI |
| Live Vaccines; Live BCG/Teplizumab SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Teplizumab may cause lymphopenia and suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(1,2) CLINICAL EFFECTS: The expected serum antibody response may not be obtained. The vaccine may result in illness.(1,2) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(3) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: The Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live-attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) Vaccination should ideally precede the initiation of teplizumab therapy by 8 weeks. Live vaccines are not recommended within the 8 weeks prior to, during, or for 52 weeks after stopping teplizumab therapy.(2) DISCUSSION: Vaccinations may be less effective if administered within 8 weeks before, during, and for 52 weeks following teplizumab therapy.(2) Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) |
TZIELD |
| Live Vaccines/Leniolisib SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Leniolisib modifies the immune system. Immune response to live vaccines may be decreased during treatment with leniolisib.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained.(1) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: The manufacturer of leniolisib states live, attenuated vaccinations may be less effective if administered during leniolisib treatment.(1) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) |
JOENJA |
There are 0 moderate interactions.
The following contraindication information is available for ROTATEQ (rotavirus vaccine, live oral pentavalent):
Drug contraindication overview.
Rotavirus vaccine live oral (Rotarix(R); RV1) is contraindicated in infants with known hypersensitivity to the vaccine or any vaccine component (e.g., latex). Rotarix(R) also is contraindicated in infants with a history of intussusception (a type of bowel obstruction that occurs when the bowel folds in on itself) or with a history of uncorrected congenital malformation of the GI tract (e.g., Meckel's diverticulum) that would predispose an infant to intussusception. In addition, the vaccine is contraindicated in infants with severe combined immunodeficiency disease (SCID).
Rotavirus vaccine live oral pentavalent (RotaTeq(R); RV5) is contraindicated in infants with known hypersensitivity to the vaccine or any vaccine component. RotaTeq(R) also is contraindicated in infants with a history of intussusception. In addition, the vaccine is contraindicated in infants with SCID.
Rotavirus vaccine live oral (Rotarix(R); RV1) is contraindicated in infants with known hypersensitivity to the vaccine or any vaccine component (e.g., latex). Rotarix(R) also is contraindicated in infants with a history of intussusception (a type of bowel obstruction that occurs when the bowel folds in on itself) or with a history of uncorrected congenital malformation of the GI tract (e.g., Meckel's diverticulum) that would predispose an infant to intussusception. In addition, the vaccine is contraindicated in infants with severe combined immunodeficiency disease (SCID).
Rotavirus vaccine live oral pentavalent (RotaTeq(R); RV5) is contraindicated in infants with known hypersensitivity to the vaccine or any vaccine component. RotaTeq(R) also is contraindicated in infants with a history of intussusception. In addition, the vaccine is contraindicated in infants with SCID.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Immunosuppression |
| Intussusception of intestine |
| Severe combined immunodeficiency disease |
There are 2 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic diarrhea |
| Malignancy |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| High fever >101 degrees fahrenheit |
The following adverse reaction information is available for ROTATEQ (rotavirus vaccine, live oral pentavalent):
Adverse reaction overview.
Rotarix(R): Adverse events reported within 8 days following the first dose of vaccine include fussiness/irritability (52%), cough/runny nose (28%), fever (25%), loss of appetite (25%), vomiting (13%), and diarrhea (4%). Frequency of adverse events within 8 days following the second dose of vaccine is similar and includes fussiness/irritability (42%), cough/runny nose (31%), fever (28%), loss of appetite (21%), vomiting (8%), and diarrhea (3%). The incidence of adverse events in the week following the first and second doses of vaccine was similar to that occurring with placebo.
RotaTeq(R): Fever has occurred in 42.6% of infants within 42 days of any dose of the vaccine; this was similar to the incidence reported with placebo. Adverse events reported within 42 days following any dose of the vaccine and reported more frequently than with placebo include diarrhea (24.1%), vomiting (15.2%), otitis media (14.5%), nasopharyngitis (6.9%), and bronchospasm (1.1%).
Rotarix(R): Adverse events reported within 8 days following the first dose of vaccine include fussiness/irritability (52%), cough/runny nose (28%), fever (25%), loss of appetite (25%), vomiting (13%), and diarrhea (4%). Frequency of adverse events within 8 days following the second dose of vaccine is similar and includes fussiness/irritability (42%), cough/runny nose (31%), fever (28%), loss of appetite (21%), vomiting (8%), and diarrhea (3%). The incidence of adverse events in the week following the first and second doses of vaccine was similar to that occurring with placebo.
RotaTeq(R): Fever has occurred in 42.6% of infants within 42 days of any dose of the vaccine; this was similar to the incidence reported with placebo. Adverse events reported within 42 days following any dose of the vaccine and reported more frequently than with placebo include diarrhea (24.1%), vomiting (15.2%), otitis media (14.5%), nasopharyngitis (6.9%), and bronchospasm (1.1%).
There are 9 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
High fever >101 degrees fahrenheit |
None. |
| Rare/Very Rare |
|---|
|
Angioedema Bloody stools Bronchospastic pulmonary disease Idiopathic thrombocytopenic purpura Intussusception of intestine Kawasaki disease Seizure disorder Urticaria |
There are 8 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute bacterial otitis media Anorexia Cough Irritability |
Diarrhea Pharyngitis Vomiting |
| Rare/Very Rare |
|---|
|
Fever |
The following precautions are available for ROTATEQ (rotavirus vaccine, live oral pentavalent):
Rotarix(R): Safety and efficacy have not been established in infants younger than 6 weeks or older than 24 weeks of age. The manufacturer states that efficacy in preterm infants has not been established. Safety data to date in preterm infants indicate serious adverse events in 5.2%
of vaccine recipients compared with 5% in placebo recipients; deaths or cases of intussusception have not been reported in this patient population to date. RotaTeq(R): Safety and efficacy have not been established in infants younger than 6 weeks or older than 32 weeks of age. The manufacturer states that RotaTeq(R) has been studied in preterm infants (i.e., gestational age 25-36 weeks), and clinical study data support use of the vaccine in such infants according to their age in weeks since birth.
Safety data in preterm infants indicate serious adverse events in 5.5% of vaccine recipients compared with 5.8% of placebo recipients; there were 2 deaths among vaccine recipients and no cases of intussusception.
Pending additional data, ACIP and AAP state that the benefits of routine vaccination with rotavirus vaccine outweigh the theoretical risks in medically stable preterm infants. These experts state that clinically stable preterm infants who meet the age requirements (at least 6 weeks and not greater than 14 weeks 6 days of age) may receive the first dose of rotavirus vaccine after or at the time of discharge from the NICU or hospital nursery. However, the possible risk of transmission of rotavirus vaccine virus to other hospitalized infants outweigh the benefits of vaccination in age-eligible infants who will remain in the NICU or nursery after the dose.
In addition, if a preterm infant who previously received rotavirus vaccine requires readmission to the NICU or hospital nursery within 2 weeks following a dose of the vaccine, contact precautions should be initiated for the preterm infant and should be maintained for 2-3 weeks following the vaccine dose. ACIP and AAP state that a replacement dose of rotavirus vaccine is not recommended if an infant receives an incomplete vaccine dose (e.g., infant spits or regurgitates the dose). (See Dosage and Administration: Reconstitution and Administration.) In limited postmarketing experience of reported overdosage of RotaTeq(R) (e.g., as the result of more than 1 dose or a replacement dose after regurgitation), adverse events reported after incorrect administration of higher than recommended doses of the vaccine were similar to adverse events reported with the recommended dosage and dosing schedule.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
of vaccine recipients compared with 5% in placebo recipients; deaths or cases of intussusception have not been reported in this patient population to date. RotaTeq(R): Safety and efficacy have not been established in infants younger than 6 weeks or older than 32 weeks of age. The manufacturer states that RotaTeq(R) has been studied in preterm infants (i.e., gestational age 25-36 weeks), and clinical study data support use of the vaccine in such infants according to their age in weeks since birth.
Safety data in preterm infants indicate serious adverse events in 5.5% of vaccine recipients compared with 5.8% of placebo recipients; there were 2 deaths among vaccine recipients and no cases of intussusception.
Pending additional data, ACIP and AAP state that the benefits of routine vaccination with rotavirus vaccine outweigh the theoretical risks in medically stable preterm infants. These experts state that clinically stable preterm infants who meet the age requirements (at least 6 weeks and not greater than 14 weeks 6 days of age) may receive the first dose of rotavirus vaccine after or at the time of discharge from the NICU or hospital nursery. However, the possible risk of transmission of rotavirus vaccine virus to other hospitalized infants outweigh the benefits of vaccination in age-eligible infants who will remain in the NICU or nursery after the dose.
In addition, if a preterm infant who previously received rotavirus vaccine requires readmission to the NICU or hospital nursery within 2 weeks following a dose of the vaccine, contact precautions should be initiated for the preterm infant and should be maintained for 2-3 weeks following the vaccine dose. ACIP and AAP state that a replacement dose of rotavirus vaccine is not recommended if an infant receives an incomplete vaccine dose (e.g., infant spits or regurgitates the dose). (See Dosage and Administration: Reconstitution and Administration.) In limited postmarketing experience of reported overdosage of RotaTeq(R) (e.g., as the result of more than 1 dose or a replacement dose after regurgitation), adverse events reported after incorrect administration of higher than recommended doses of the vaccine were similar to adverse events reported with the recommended dosage and dosing schedule.
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Rotavirus vaccine is not indicated for use in adults, including pregnant women. ACIP and AAP state that infants living in households with pregnant women may receive rotavirus vaccine. Most women of childbearing age would be expected to have preexisting immunity to rotavirus.
Most experts agree that the risk of acquiring rotavirus infection from potential exposure to the vaccine virus is very low. In addition, there is no evidence that infection with rotavirus during pregnancy poses any risk to the fetus. Furthermore, vaccination of infants against rotavirus avoids potential exposure of pregnant women to natural rotavirus from unvaccinated infants with rotavirus gastroenteritis.
Most experts agree that the risk of acquiring rotavirus infection from potential exposure to the vaccine virus is very low. In addition, there is no evidence that infection with rotavirus during pregnancy poses any risk to the fetus. Furthermore, vaccination of infants against rotavirus avoids potential exposure of pregnant women to natural rotavirus from unvaccinated infants with rotavirus gastroenteritis.
Rotavirus vaccine is not indicated for use in adults, including nursing women. ACIP and AAP state that nursing infants may receive rotavirus vaccine, since efficacy of the vaccine in breast-feeding infants is similar to that in infants not breast-feeding.
Rotavirus vaccine is not recommended for use in adults, including geriatric adults.
The following prioritized warning is available for ROTATEQ (rotavirus vaccine, live oral pentavalent):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ROTATEQ (rotavirus vaccine, live oral pentavalent)'s list of indications:
| Rotavirus vaccination | |
| Z23 | Encounter for immunization |
Formulary Reference Tool